GENMAB A

Genmab A/S is a biotechnology company based in Copenhagen, Denmark, that develops antibody-based products and product candidates for treating cancer and other diseases. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL). It also offers Tivdak for adult patients with recurrent/metastatic cervical cancer that has progressed on or after chemotherapy. Genmab A/S is developing Epcoritamab for R/R DLBCL and FL, first-line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients. Other product candidates include tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum-resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. The company also provides DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Additionally, Genmab A/S is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occlusive crises in sickle cell diseases; and Mim8 for hemophilia A. The company, incorporated in 1998, has collaboration agreements with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx.